Deep Dive: Biotech stocks have been hit hard — here are ones analysts like best for a rebound

October was a difficult month for investors, who watched the S&P 500 Index’s swift 6.8% descent.

Leading technology companies dominated the alarming headlines (Amazon.com AMZN, -0.03% dropped 20%, and Netflix NFLX, -2.93% fell 19%). But digging further, the biotechnology subsector was down 13.4%.

That spells opportunities for long-term investors, which Michael Brush explained while looking at stock prices relative to Jefferies analyst Michael Yee’s estimated values of their product pipelines. You effectively can acquire product pipelines of great potential for next to nothing if you buy shares of Gilead Sciences GILD, -0.83% or Celgene CELG, -0.30% according to Brush.

>>> Original Source <<<